Status:
UNKNOWN
Comprehensive Analysis of Hypoxia in Prostate Cancer: Diagnostic Markers and Prognostic Significance
Lead Sponsor:
University of Zurich
Conditions:
Prostate Cancer
Eligibility:
MALE
Brief Summary
A single-center cohort study to identify uni- and multivariate associations between marker gene expression and clinico-pathological parameters for the detection of robust and novel prognostic tools in...
Detailed Description
1. To perform a large scale assessment of tissue hypoxia by pimonidazole and hypoxia marker gene expression in human prostate cancers 2. To characterize expression and hypoxia/HIF-responsiveness of my...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients with biopsy-proven adenocarcinoma of the prostate who are to be treated with radical prostatectomy at the Department of Urology, University Hospital of Zurich
- Written informed consent
- Exclusion criteria:
- Metastatic prostate cancer
- Contraindications to the class of investigational product under study, e.g. known hypersensitivity or allergy to the investigational product
- Severe heart or lung disease
- Severe liver or kidney dysfunction
- Severe stridor
- Distant metastases
- Concurrent treatment for other malignant disease
- Prior hormonal therapy or radiotherapy
Exclusion
Key Trial Info
Start Date :
August 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2020
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT01191099
Start Date
August 1 2010
End Date
August 1 2020
Last Update
November 8 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Zürich
Zurich, Switzerland, 8091